Skip to main content
Premium Trial:

Request an Annual Quote

New Product Watch: Feb 3, 2009


Navigenics last week launched Annual Insight, a direct-to-consumer genetic testing service available for $499 that provides information on an individual’s genetic predisposition for common preventable health conditions.

Annual Insight analyzes an individual’s genetic predisposition for ten common health conditions, including breast cancer, prostate cancer, colon cancer and heart disease. The service will be available to consumers through participating healthcare providers or directly from Navigenics’ website with genetic counselor support.

Navigenics last week also launched Physician Portal, a resource that enables physicians to receive and review patients' genetic results online, with access to condition information, action steps, and original scientific research. Access to the physician portal is free to physicians who register their practice, the company said.

Navigenics uses Affymetrix SNP arrays in its service.

ImaGenes last week began offering global DNA methylation analysis as a service in its Berlin labs. The service provides genome-wide analysis of DNA methylation profiles for the identification of genetic markers, the company said.

ImaGenes methylation analysis service makes use of Diagenode’s MagMeDIP Kit, a labeling system using 5-methyl cytidine antibodies coated on magnetic beads. ImaGenes offers profiling on the Affymetrix, Illumina, Agilent Technologies, and Roche NimbleGen microarray platforms.

Ocimum Biosolutions last week launched version 4.1 of its Biotracker R&D Life Science Laboratory Information Management System.

The version 4.1 release enables users to access Biotracker via a web-services-based API, as well as a Java-based API. Biotracker 4.1 also includes over 100 core enhancements that improve searching, reporting, auditing, processing, and usability, Ocimum said.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.